FIELD: medicine.
SUBSTANCE: invention refers to biotechnology, more specifically to a response test to the hospital infection in a patient suffering from a septic shock, and can be used in medicine. A biological sample specified in the patient's blood, serum, saliva, tissue or circulating cells is prepared, and a biological material: nucleic acid or protein is extracted from the biological sample. A reagent specific to the S100A9 target gene expression product specified in an amplification primer, a hybridisation probe and/or antibody is used to determine the S100A9 target gene expression.
EFFECT: invention enables stating the response to the hospital infection in the patient suffering from the septic shock as shown by the S100A9 target gene overexpression to a certain threshold.
11 cl, 2 dwg, 3 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR DETERMINING PATIENT'S SUSCEPTIBILITY TO NOSOCOMIAL INFECTION AND PREDICTING DEVELOPMENT OF A SEPTIC SYNDROME | 2014 |
|
RU2663724C2 |
| IDENTIFICATION OF TUMOUR-ASSOCIATED ANTIGENS FOR DIAGNOSTICS AND THERAPY | 2013 |
|
RU2644686C2 |
| METHOD OF DIAGNOSING NEOPLASM-II | 2008 |
|
RU2565540C2 |
| METHODS AND KITS FOR MOLECULAR SUBTYPING OF TUMORS | 2014 |
|
RU2690241C2 |
| METHODS AND COMPOSITIONS RELATED TO FUSION OF ALPHA-LINOLENIC ACID FOR PURPOSES OF CANCER DETECTION AND TREATMENT | 2010 |
|
RU2562144C2 |
| DIAGNOSTIC TECHNIQUE FOR BLADDER CANCER (VERSIONS) AND KIT FOR IMPLEMENTATION THEREOF | 2011 |
|
RU2469323C2 |
| MULTIPARAMETRIC DIAGNOSTIC TEST SYSTEM FOR QUANTITATIVE DETERMINATION OF MRNA LEVEL OF HUMAN RIG-1, IFIT-1, IFIH-1 GENES | 2021 |
|
RU2782428C1 |
| DIAGNOSTIC TECHNIQUE FOR BLADDER CANCER BY CANCER-SPECIFIC MARKER TEDP1 (VERSIONS) AND KIT FOR IMPLEMENTING IT | 2011 |
|
RU2463354C1 |
| METHOD FOR ESTIMATING CLINICAL EFFECTIVENESS OF HUMAN BLADDER CANCER BY REAL-TIME PCR AND KIT FOR IMPLEMENTATION THEREOF | 2011 |
|
RU2469098C2 |
| METHOD FOR CARRYING OUT DIAGNOSTIC ANALYSIS | 2001 |
|
RU2228530C2 |
